Opus Genetics stock analysis
Want to see IRD full AI Analyst Report?
Opus Genetics (IRD) Stock Price & Analysis
IRD Stock Chart & Stats
- Day’s Range
- $3.80 - $4.17
- 52-Week Range
- $1.70 - $7.07
- Previous Close
- $4.06
- Volume
- N/A
- Average Volume (3M)
- 1.40M
- Market Cap
- $384.68M
- Enterprise Value
- $439.82M
- Total Cash (Recent Filing)
- $88.97M
- Total Debt (Recent Filing)
- $34.53M
- Price to Earnings (P/E)
- ―
- Beta
- 0.60
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- -0.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory Progress
Positive clinical findings combined with FDA alignment reduce development uncertainty for OPGx-BEST1. If follow-up data remain supportive, the clearer endpoint and planned pivotal path could improve the program’s probability of advancing toward commercialization.
OPGx-LCA5 Phase 3 Advancement
A fully enrolled registrational trial represents meaningful execution progress and moves OPGx-LCA5 closer to a potential regulatory decision. This creates a nearer-term development milestone and diversifies the company’s clinical pipeline beyond earlier-stage programs.
Expanding Gene Therapy Pipeline
IND clearance for a third gene therapy program broadens Opus Genetics’ pipeline and supports a multi-asset development strategy. Additional programs can create more opportunities for clinical success and reduce reliance on any single inherited retinal disease candidate.
Bears Say
Contracting Revenue
Declining revenue indicates that the company’s current commercial or partnered revenue base is not yet providing dependable growth. A smaller revenue foundation limits internal funding capacity and leaves future financial performance highly dependent on clinical and regulatory milestones.
Severe Operating Losses
Losses are extremely large relative to the revenue base, showing that operating costs currently overwhelm incoming revenue. Persistent negative profitability can increase dependence on external financing and makes the business more vulnerable if development timelines extend or programs underperform.
Heavy Cash Burn
Sustained negative operating and free cash flow means the company is consuming cash rather than funding development internally. Continued burn implies ongoing financing needs, which may constrain strategic flexibility and could increase dilution or funding pressure while losses persist.
Opus Genetics News
IRD FAQ
What was Opus Genetics’s price range in the past 12 months?
What is Opus Genetics’s market cap?
When is Opus Genetics’s upcoming earnings report date?
How were Opus Genetics’s earnings last quarter?
Is Opus Genetics overvalued?
Does Opus Genetics pay dividends?
What is Opus Genetics’s EPS estimate?
How many shares outstanding does Opus Genetics have?
What happened to Opus Genetics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Opus Genetics?
What is the TipRanks Smart Score and how is it calculated?
Opus Genetics Stock Smart Score
Company Description
Opus Genetics
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- George Magrath
- Employees
- 28
- Website
- opusgtx.com
- Address
- 8 Davis Drive, Durham, NC, 27713, US
Opus Genetics (IRD) Earnings & Revenues
IRD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 2 | 0 | 10 |













